Department of Family Medicine, Faculty of Medicine and Health Sciences, McGill University, 5858 Chemin de la Côte-des-Neiges, Suite 300, Montreal, QC, H3S 1Z1, Canada.
Department of Anesthesia, Faculty of Medicine and Health Sciences, McGill University, 1650 Cedar Ave., Montreal, QC, H3G 1A4, Canada.
Syst Rev. 2021 Nov 15;10(1):298. doi: 10.1186/s13643-021-01852-w.
The North American opioid crisis is driven by opioid-related mortality and morbidity, including opioid use-associated infections (OUAIs), resulting in a substantial burden for society. Users of legal and illegal opioids are at an increased risk of OUAIs compared to individuals not using opioids. As reported for hepatitis C virus (HCV), human immunodeficiency virus (HIV), bacterial, fungal, and other infections, OUAIs transmission and acquisition risks may be modifiable. Several systematic reviews (SRs) synthetized data regarding interventions to prevent infections in persons using drugs (e.g., opioid substitution therapy, needle and syringes exchange programs, psycho-social interventions); however, their conclusions varied. Therefore, SR of published SRs is needed to synthesize the highest level of evidence on the scope and effectiveness of interventions to prevent OUAIs in people using opioids legally or illegally.
We will comprehensively search for SRs in the PubMed, Embase, PsycINFO, Cochrane Database of Systematic Reviews, Epistemonikos, and Google Scholar databases from inception to November 2020. Data selection and extraction for each SR will be performed independently by two researchers, with disagreements resolved by consensus. All SRs regarding interventions with evaluated effectiveness to prevent OUAI in legal and/or illegal opioid users will be eligible. Risk of bias assessment will be performed using the AMSTAR2 tool. The results will be qualitatively synthesized, and a typology of interventions' effectiveness with a statement on the strength of evidence for each category will be created.
Our pilot search of PubMed resulted in 379 SRs analyzing the effectiveness of interventions to prevent HCV and HIV in persons who inject different types of drugs, including opioids. Of these 379 SRs, 8 evaluated primary studies where participants used opioids and would therefore be eligible for inclusion. The search results thus justify the application of SR of SRs approach. Comprehensive data on the scope and effectiveness of existing interventions to prevent OUAIs will help policy-makers to plan and implement preventive interventions and will assist clinicians in the guidance for their patients using opioids.
Registered in PROSPERO on 30 July 2020 ( #195929 ).
北美阿片类药物危机是由阿片类药物相关的死亡率和发病率驱动的,包括阿片类药物使用相关感染(OUAIs),给社会带来了巨大的负担。与未使用阿片类药物的个体相比,合法和非法使用阿片类药物的个体发生 OUAIs 的风险更高。正如丙型肝炎病毒(HCV)、人类免疫缺陷病毒(HIV)、细菌、真菌和其他感染的报告所述,OUAIs 的传播和获得风险可能是可以改变的。几项系统评价(SR)综合了关于预防吸毒者感染的干预措施的数据(例如,阿片类药物替代疗法、针和注射器交换方案、心理社会干预);然而,他们的结论各不相同。因此,需要对已发表的 SR 进行 SR 综述,以综合评估预防合法或非法使用阿片类药物者发生 OUAIs 的干预措施的范围和效果的最高证据水平。
我们将从建立到 2020 年 11 月全面检索 PubMed、Embase、PsycINFO、Cochrane 系统评价数据库、Epistemonikos 和 Google Scholar 数据库中的 SR。每个 SR 的数据选择和提取将由两名研究人员独立进行,如果存在分歧,将通过共识解决。所有关于预防合法和/或非法阿片类药物使用者发生 OUAIs 的干预措施且具有评估有效性的 SR 均符合入选标准。将使用 AMSTAR2 工具进行偏倚风险评估。结果将进行定性综合,并创建一个干预效果分类的干预效果分类,并对每个类别提出证据强度的声明。
我们对 PubMed 的初步搜索结果显示,有 379 项 SR 分析了预防不同类型药物(包括阿片类药物)使用者感染 HCV 和 HIV 的干预措施的有效性。在这 379 项 SR 中,有 8 项评估了参与者使用阿片类药物的原始研究,因此符合入选标准。因此,搜索结果证明了 SR 综述方法的应用是合理的。关于预防 OUAIs 的现有干预措施的范围和有效性的综合数据将有助于政策制定者规划和实施预防干预措施,并为临床医生指导使用阿片类药物的患者提供帮助。
于 2020 年 7 月 30 日在 PROSPERO 注册(#195929)。